Merck announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus ... Individual.com, 5 hours ago
On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - National AIDS Treatment Advocacy Project, 3 days ago
Merck's Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection - CNBC, 4 days ago
2 images for "Mk 5172"
March 8, 2014 Merck's Hep C Drugs Show Promise for HIV Coinfection Promising preliminary results from a trial of Merck's MK-5172 and MK-8742, given with or without ribavirin, showed that the combination therapy was ...AIDSmeds, 1 day ago Merck hepatitis C drugs work in HIV co-infected patients -study Yahoo! Finance, 4 days ago
Gilead's hepatology fanbase may be set to split. In addition to yesterday's AbbVie news that its three-D combination of an HCV protease inhibitor, NS5A inhibitor and NS5B inhibitor was shown to clear the virus after 12 weeks of therapy, Merck ...Medical Marketing And Media, 3 days ago
Bio-Path Holdings Inc. (BPTH.OB) has received approval to uplist its shares to the NASDAQ Capital Market. Accordingly, the stock will commence trading on the NASDAQ Capital Market under the symbol BPTH from March 10, 2014. CytRx Corp. (CYTR: Quote) ...RTTNews.com, 4 days ago
Current Awards 2/28/2014 Sole Source #14-22 C5434 KIVA (DMS) Replacement, Dept. of Management $250,000.00 Gartner, Inc. 2/28/2014 IFBNo. 13-14/P-28 C5473 Furnish & Delivery of One (1) 6x6 66,000 Lb. GVW Truck Cab and Chassis with ...Maui County, 4 days ago
ess Wire AA + - Devon Energy Corporation (NYSE:DVN) today announced that its board of directors has approved a 9 percent increase to its quarterly cash dividend on the company's common stock from $0.22 per share to $0.24 per share. The ...Investing.com, 4 days ago
ess Wire AA + - Ecolab Inc.'s Michael Hickey, executive vice president and president, Global Institutional, will address financial analysts at the Credit Suisse Global Services Conference on Monday, March 10 in Phoenix, Ariz. Ecolab will ...Investing.com, 4 days ago
By a News Reporter-Staff News Editor at Ecology, Environment & Conservation -- Investigators discuss new findings in Environmental Water Research . According to news originating from Mymensingh, Bangladesh , by VerticalNews correspondents, research ...Water Environment Federation, 4 days ago
MERCK & CO. INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
(Edgar Glimpses Via Acquire Media NewsEdge) Description of Merck's Business Merck & Co., Inc. ("Merck" or the "Company") is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic ...TMC Net, 1 week ago Merck & Co, Inc.: Big Pharma Checkup for 2014 Daily Finance, 1 month ago
Boston—Over the next five years, a whirlwind of new direct-acting antiviral agents (DAAs) for hepatitis C are expected to get the green light from the FDA. The recent approval of simeprevir (Olysio, Janssen) and sofosbuvir (Sovaldi, ...Pharmacy Practice News, 1 week ago
on your WebpageAdd Widget >Get your members hooked!